Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$824.48 USD

824.48
780,900

+7.83 (0.96%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $824.95 +0.47 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Regeneron (REGN) Stock on Fire: What's Behind the Surge?

Shares of Regeneron Pharmaceuticals, Inc. (REGN) have moved up 14.8% over the last 30 days.

    Here's Why Geron (GERN) is a Good Stock to Invest in Now

    Geron Corporation (GERN) is developing anti-cancer therapies based on telomerase inhibitors.

      BioDelivery Inks New Contract with CVS/Caremark, Shares Up

      BioDelivery Sciences International, Inc. (BDSI) announced an agreement with CVS/Caremark to extend access to its pain management product Belbuca and opioid dependence product Bunavail through 2020.

        Indivor's Opioid Use Disorder Drug Meets Primary Endpoint

        Indivior PLC (INVVY) announced that a pivotal study (RB-US-13-0001) evaluating its candidate, RBP-6000, in patients with moderate-to-severe opioid use disorder (OUD) met its primary endpoint.

          AveXis (AVXS) Jumps: Stock Rises 7.1%

          AveXis, Inc.(AVXS) was a big mover last session, as the company saw its shares rise over 7% on the day.

            Strength Seen in Arena Pharmaceuticals (ARNA): Stock Up 5.4%

            Arena Pharmaceuticals, Inc. (ARNA) shares rose over 5% in the last trading session.

              Novartis Migraine Drug Accepted, AMD Positive in Phase III

              Novartis (NVS) announced that the EMA accepted its application for migraine candidate AMG 334.

                Tirthankar Chakraborty headshot

                Fresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys

                IBB surged 17% since Trump's win but is still down 23% from its all-time intraday high scaled in the July of 2015.

                  Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8%

                  Vanda Pharmaceuticals Inc. (VNDA) shares rose over 8% in the last trading session.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt

                    Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.

                      J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study

                      Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

                        Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA

                        Rigel Pharmaceuticals, Inc. (RIGL) announced that the FDA has accepted its new drug application (NDA) seeking approval for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenia

                          Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA

                          Amgen Inc. (AMGN) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva.

                            Merrimack Completes Enrollment in Phase II Study for MM-141

                            Merrimack Pharmaceuticals announced completion of enrollment in the ongoing phase II study, evaluatingMM-141 in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer.

                              CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zacks Bull and Bear of the Day

                              CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zacks Bull and Bear of the Day

                                John Blank headshot

                                A Lazy, Unfocused Summer Is Here: Global Week Ahead

                                A lazy, unfocused summer is here. Yet that sentiment might be bullish stocks. No new news may be good news -- in this upward trending market -- driven by momentum, mostly.

                                  GlaxoSmithKline's Benlysta Positive in Continuation Trial

                                  GlaxoSmithKline plc (GSK) announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug, Benlysta, in combination with standard of care for treatment systemic lupus erythematosus (SLE).

                                    Pfizer & Lilly Get Fast Track Designation for Pain Candidate

                                    Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).

                                      Zacks.com featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Dollar General, Xcel Energy and Morgan Stanley

                                      Zacks.com featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Dollar General, Xcel Energy and Morgan Stanley

                                        GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up

                                        GTx, Inc.'s (GTXI) shares have climbed almost 99% after the company announced positive data from a phase II study, evaluating enobosarm for treating postmenopausal women with stress urinary incontinence.

                                          5 Stocks with Solid Sales Growth Catching Eyeballs

                                          Sales growth is an important indicator of a company's health and ability to sustain its business. It offers investors an insight into product demand and pricing power.

                                            Lilly Plans New Outcomes Study to Expand Jardiance Label

                                            Eli Lilly and Company (LLY) along with partner Boehringer Ingelheim are planning to conduct a new outcomes study to evaluate the type II diabetes drug Jardiance (empagliflozin) for treatment of patients with chronic kidney disease.

                                              J&J Announces EU Regulatory Approval for Actelion Deal

                                              Johnson & Johnson (JNJ) has received a regulatory approval from the European Commission (EC), thus completing all necessary formalities to close the pending acquisition of Swiss biopharmaceutical company, Actelion Ltd.

                                                Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies

                                                Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that their PCSK9 inhibitor, Praluent significantly reduced bad cholesterol in two late-stage studies.

                                                  Regeneron (REGN) Up 7.3% Since Earnings Report: Can It Continue?

                                                  Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.